By Stephen Nakrosis
Shares of Acorda Therapeutics Inc. are trading higher in Thursday's after-hours market, following the company's announcement it entered agreements with Esteve Pharmaceuticals S.A to commercialize Inbrija 33 mg in Spain.
Acorda said it will supply Inbrija and receive a "significant double-digit percent" of the selling price in Spain.
At 6:05 p.m. ET, the company's shares were trading 24.67% higher at $4.75. Volume at the time topped 645,000 shares.
The company's stock finished the day's regular-trading session with a 45.27% loss, closing at $3.81.
Write to Stephen Nakrosis at [email protected]